Literature DB >> 35989895

Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada.

Ahmad Shakeri1, Kaleen N Hayes2, Tara Gomes3,4,5, Mina Tadrous1,3.   

Abstract

Entities:  

Keywords:  Canada; antiviral; health policy; hepatitis C; prescription drugs

Year:  2021        PMID： 35989895      PMCID： PMC9235118          DOI： 10.3138/canlivj-2020-0041

Source DB:  PubMed          Journal:  Can Liver J        ISSN： 2561-4444


× No keyword cloud information.
  11 in total

1.  Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions.

Authors:  Samantha Myers; Gurleen Khosa; I Fan Kuo; Donica Janzen; Silvia Alessi-Severini
Journal:  J Pharm Pharm Sci       Date:  2018       Impact factor: 2.327

2.  Direct-acting antiviral treatment for hepatitis C.

Authors:  Jacinta A Holmes; Stephanie M Rutledge; Raymond T Chung
Journal:  Lancet       Date:  2019-02-11       Impact factor: 79.321

3.  Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018.

Authors:  Ahmad Shakeri; Narthaanan Srimurugathasan; Katie J Suda; Tara Gomes; Mina Tadrous
Journal:  Value Health       Date:  2020-07-28       Impact factor: 5.725

4.  Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.

Authors:  Michael Crosby; Mina Tadrous; Tara Gomes
Journal:  Clin Pharmacol Ther       Date:  2020-10-03       Impact factor: 6.875

5.  Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program.

Authors:  Mina Tadrous; Simon Greaves; Diana Martins; Muhammad M Mamdani; David N Juurlink; Tara Gomes
Journal:  CMAJ Open       Date:  2018-03-14

6.  National trends in prescription drug expenditures and projections for 2020.

Authors:  Eric M Tichy; Glen T Schumock; James M Hoffman; Katie J Suda; Matthew H Rim; Mina Tadrous; JoAnn Stubbings; Sandra Cuellar; John S Clark; Michelle D Wiest; Linda M Matusiak; Robert J Hunkler; Lee C Vermeulen
Journal:  Am J Health Syst Pharm       Date:  2020-07-23       Impact factor: 2.637

7.  Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults.

Authors:  Cody D Black; Lisa McCarthy; Tara Gomes; Muhammad Mamdani; David Juurlink; Mina Tadrous
Journal:  Can Geriatr J       Date:  2018-09-30

8.  Estimated prevalence of Hepatitis C Virus infection in Canada, 2011.

Authors:  M Trubnikov; P Yan; C Archibald
Journal:  Can Commun Dis Rep       Date:  2014-12-18

9.  The impact of infection on population health: results of the Ontario burden of infectious diseases study.

Authors:  Jeffrey C Kwong; Sujitha Ratnasingham; Michael A Campitelli; Nick Daneman; Shelley L Deeks; Douglas G Manuel; Vanessa G Allen; Ahmed M Bayoumi; Aamir Fazil; David N Fisman; Andrea S Gershon; Effie Gournis; E Jenny Heathcote; Frances B Jamieson; Prabhat Jha; Kamran M Khan; Shannon E Majowicz; Tony Mazzulli; Allison J McGeer; Matthew P Muller; Abhishek Raut; Elizabeth Rea; Robert S Remis; Rita Shahin; Alissa J Wright; Brandon Zagorski; Natasha S Crowcroft
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

Review 10.  Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.

Authors:  Jaden Brandt; Brenna Shearer; Steven G Morgan
Journal:  J Pharm Policy Pract       Date:  2018-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.